Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsColorado Rocky Mountain Voxzogo Coverage | OpenPay…
    Ask Trek AI about this page
    CurrentColorado Rocky Mountain Health PlansPolicy N/A

    Voxzogo (vosoritide) Coverage

    Customize your policy alerts

    Sign up for all Colorado Rocky Mountain Health Plans policy alerts

    Know when Colorado Rocky Mountain Health Plans releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and reauthorization for Voxzogo in pediatric patients with achondroplasia. Coverage applies to eligible patients under 18 years of age with open epiphyses, subject to clinical response requirements for continuation and restrictions against combination use with another CNP analog.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyVoxzogo (vosoritide) Coverage
    Policy CodePolicy N/A
    Change TypeMaterial revision
    Effective DateNov 1, 2026
    Last ReviewDec 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization and document achondroplasia, age under 18 years, open epiphyses, and no concurrent use of another CNP analog.
    SourceLink
    POLICY UPDATE CHANGES

    The policy added a requirement that Voxzogo not be used in combination with another C-type natriuretic peptide analog for both initial authorization and reauthorization.

    The policy added a patient age requirement of less than 18 years to the reauthorization criteria.

    The policy added an open-epiphyses requirement to reauthorization criteria.

    The policy expanded the background indication to pediatric patients of all ages before the current coverage criteria specified an age limit of less than 18 years.

    <18 years

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Maximum patient age for authorization
    Open epiphysesRequired skeletal maturity
    12 monthsInitial authorization duration
    12 monthsReauthorization duration
    4Initial criteria required

    Coverage Criteria

    Initial Authorization

    Covered when all of the following are met:

    Initial authorization criteria

    • Diagnosis: Patient has a diagnosis of achondroplasia.
    • Age: Patient is younger than 18 years of age.<18 years
    • Skeletal maturity: Patient has open epiphyses.
    • No combination CNP analog therapy: Voxzogo will not be used in combination with another C-type natriuretic peptide (CNP) analog, such as Yuviwel (navepegritide).

    Reauthorization

    Covered when all of the following are met:

    Reauthorization criteria

    • Clinical response: There is documentation of a positive clinical response to Voxzogo therapy.
    • Age: Patient is younger than 18 years of age.<18 years
    • Skeletal maturity: Patient has open epiphyses.
    • No combination CNP analog therapy: Voxzogo will not be used in combination with another C-type natriuretic peptide (CNP) analog, such as Yuviwel (navepegritide).

    Voxzogo must not be used in combination with another C-type natriuretic peptide (CNP) analog, including Yuviwel (navepegritide). This restriction applies to both initial authorization and reauthorization.

    Provider Actions

    Prior Authorization

    Initial Authorization Required

    Prior authorization is required for initial Voxzogo therapy. Approval is available for 12 months when all initial authorization criteria are met.

    • Diagnosis of achondroplasia
    • Patient is under 18 years of age
    • Presence of open epiphyses
    • Voxzogo is not used in combination with another C-type natriuretic peptide (CNP) analog, such as Yuviwel (navepegritide)
    Documentation Required

    Reauthorization Requirements

    Submit reauthorization documentation demonstrating continued eligibility and clinical benefit. Reauthorization, when approved, is issued for 12 months.

    • Documentation of a positive clinical response to Voxzogo therapy

    Background

    Voxzogo (vosoritide) is a C-type natriuretic peptide analog indicated to increase linear growth in pediatric patients with achondroplasia and open epiphyses. The indication was granted under accelerated approval based on improvement in annualized growth velocity; continued approval may depend on verification and description of clinical benefit in confirmatory trials.

    Definitions

    Voxzogo (vosoritide)
    MedicationVoxzogo (vosoritide)
    Drug classC-type natriuretic peptide (CNP) analog
    Indicated useIncrease linear growth in pediatric patients with achondroplasia and open epiphyses
    Approval basisApproved under accelerated approval based on improvement in annualized growth velocity
    Open epiphyses
    DefinitionGrowth plates at the ends of bones that remain open and permit further linear growth
    Clinical relevanceRequired for Voxzogo use in pediatric patients with achondroplasia

    Initial Therapy Criteria

    Voxzogo Initial Authorization

    Initial authorization is approved when all criteria are met:

    Initial therapy criteria

    • Diagnosis: Patient has a diagnosis of achondroplasia.
    • Age: Patient is younger than 18 years of age.<18 years
    • Skeletal maturity: Patient has open epiphyses.
    • No combination CNP analog therapy:

    Continuation Criteria

    Voxzogo Reauthorization

    Reauthorization is approved when all criteria are met:

    Continuation criteria

    • Clinical response: There is documentation of a positive clinical response to Voxzogo therapy.
    • Age: Patient is younger than 18 years of age.<18 years
    • Skeletal maturity: Patient has open epiphyses.
    • No combination CNP analog therapy:
    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyVoxzogo (vosoritide) Coverage
    Policy CodePolicy N/A
    Change TypeMaterial revision
    Effective DateNov 1, 2026
    Last ReviewDec 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization and document achondroplasia, age under 18 years, open epiphyses, and no concurrent use of another CNP analog.
    SourceLink
    On This Page
    Coverage CriteriaProvider ActionsBackgroundDefinitionsInitial Therapy CriteriaContinuation Criteria
  1. Patient remains under 18 years of age
  2. Presence of open epiphyses
  3. Voxzogo is not used in combination with another CNP analog, such as Yuviwel (navepegritide)
  4. Documentation Required

    Document Clinical Response

    Document the member’s positive clinical response to Voxzogo therapy in the reauthorization request. This documentation is required for continued approval.

    Denial Risk

    Initial Eligibility Requirements Not Met

    Initial authorization will be denied when any required eligibility criterion is not met, including diagnosis, age, open epiphyses, or the prohibition on combination therapy with another CNP analog.

    • No diagnosis of achondroplasia
    • Patient is 18 years of age or older
    • Epiphyses are not open
    • Voxzogo will be used in combination with another CNP analog, such as Yuviwel (navepegritide)
    Denial Risk

    Continuation Requirements Not Met

    Reauthorization will be denied when continued approval requirements are not met or required documentation is absent.

    • No documented positive clinical response to Voxzogo therapy
    • Patient is 18 years of age or older
    • Epiphyses are not open
    • Voxzogo will be used in combination with another CNP analog, such as Yuviwel (navepegritide)
    Coverage criterionThe patient must have open epiphyses for initial authorization and reauthorization
    Voxzogo will not be used in combination with another C-type natriuretic peptide (CNP) analog, such as Yuviwel (navepegritide).
    Voxzogo will not be used in combination with another C-type natriuretic peptide (CNP) analog, such as Yuviwel (navepegritide).